The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Deep Brain Stimulation in Moroccan Patients With Parkinson's Disease: The Experience of Neurology Department of Rabat
|
|---|---|
| Published in |
Frontiers in Neurology, July 2018
|
| DOI | 10.3389/fneur.2018.00532 |
| Pubmed ID | |
| Authors |
Mounia Rahmani, Maria Benabdeljlil, Fouad Bellakhdar, Mustapha El Alaoui Faris, Mohamed Jiddane, Khalil El Bayad, Fatima Boutbib, Rachid Razine, Rachid Gana, Moulay R. El Hassani, Nizar El Fatemi, Meryem Fikri, Siham Sanhaji, Hennou Tassine, Imane El Alaoui Balrhiti, Souad El Hadri, Najwa Ech-Cherif Kettani, Najia El Abbadi, Mourad Amor, Abdelmjid Moussaoui, Afifa Semlali, Saadia Aidi, El Hachmia Ait Benhaddou, Ali Benomar, Ahmed Bouhouche, Mohamed Yahyaoui, Abdeslam El Khamlichi, Abdessamad El Ouahabi, Rachid El Maaqili, Houyam Tibar, Yasser Arkha, Adyl Melhaoui, Abdelhamid Benazzouz, Wafa Regragui |
| Abstract |
Introduction: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is known as a therapy of choice of advanced Parkinson's disease. The present study aimed to assess the beneficial and side effects of STN DBS in Moroccan Parkinsonian patients. Material and Methods: Thirty five patients underwent bilateral STN DBS from 2008 to 2016 in the Rabat University Hospital. Patients were assessed preoperatively and followed up for 6 to 12 months using the Unified Parkinson's Disease Rating Scale in four conditions (stimulation OFF and ON and medication OFF and ON), the levodopa-equivalent daily dose (LEDD), dyskinesia and fluctuation scores and PDQ39 scale for quality of life (QOL). Postoperative side effects were also recorded. Results: The mean age at disease onset was 42.31 ± 7.29 years [28-58] and the mean age at surgery was 54.66 ± 8.51 years [34-70]. The median disease duration was 11.95 ± 4.28 years [5-22]. Sixty-three percentage of patients were male. 11.4% of patients were tremor dominant while 45.71 showed akinetic-rigid form and 42.90 were classified as mixed phenotype. The LEDD before surgery was 1200 mg/day [800-1500]. All patients had motor fluctuations whereas non-motor fluctuations were present in 61.80% of cases. STN DBS decreased the LEDD by 51.72%, as the mean LEDD post-surgery was 450 [188-800]. The UPDRS-III was improved by 52.27%, dyskinesia score by 66.70% and motor fluctuations by 50%, whereas QOL improved by 27.12%. Post-operative side effects were hypophonia (2 cases), infection (3 cases), and pneumocephalus (2 cases). Conclusion: Our results showed that STN DBS is an effective treatment in Moroccan Parkinsonian patients leading to a major improvement of the most disabling symptoms (dyskinesia, motor fluctuation) and a better QOL. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 47 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 12 | 26% |
| Other | 4 | 9% |
| Student > Doctoral Student | 3 | 6% |
| Researcher | 3 | 6% |
| Student > Ph. D. Student | 2 | 4% |
| Other | 5 | 11% |
| Unknown | 18 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 17% |
| Neuroscience | 5 | 11% |
| Nursing and Health Professions | 2 | 4% |
| Psychology | 2 | 4% |
| Engineering | 2 | 4% |
| Other | 6 | 13% |
| Unknown | 22 | 47% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 August 2018.
All research outputs
#15,012,809
of 23,094,276 outputs
Outputs from Frontiers in Neurology
#6,198
of 12,012 outputs
Outputs of similar age
#197,952
of 329,834 outputs
Outputs of similar age from Frontiers in Neurology
#145
of 315 outputs
Altmetric has tracked 23,094,276 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 12,012 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 329,834 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 315 others from the same source and published within six weeks on either side of this one. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.